<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00036036</url>
  </required_header>
  <id_info>
    <org_study_id>OSI-461-003</org_study_id>
    <nct_id>NCT00036036</nct_id>
  </id_info>
  <brief_title>Study of CP-461 in Patients With Advanced Renal Cell Cancer</brief_title>
  <official_title>Phase II Study of CP-461 in Patients With Advanced Renal Cell Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OSI Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of CP-461 given twice-daily orally in
      locally advanced or metastatic renal cell cancer and to evaluate the safety profile of CP-461
      in this patient population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2001</start_date>
  <completion_date type="Actual">July 2003</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment>14</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-461</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Measurable metastatic or locally advanced disease.

          2. Histologically confirmed renal cell cancer.

          3. No radiotherapy within 4 weeks prior to entering the study. No more than 1 prior
             systemic therapy for advanced disease. Prior adjuvant systemic therapy is allowed.
             Patients must have fully recovered from the acute effects of prior therapy.

          4. Expected remaining life span &gt; or = three months.

          5. ECOG performance status 0-2.

          6. &gt; or = 18 years of legal age.

          7. Male patients, or non-pregnant and non-lactating female patients who are either using
             adequate birth control, surgically sterile or post-menopausal.

          8. Negative serum pregnancy test, if fertile female.

          9. Willingness and ability to sign an informed consent document.

        Exclusion Criteria:

          1. Uncontrolled or symptomatic brain metastases.

          2. Use of an investigational medication or device within one month of initiating study
             therapy.

          3. Absolute granulocyte count &lt; or = 1500/mm3; Platelet count &lt; or = 100,000/mm3; total
             serum bilirubin above the upper limit of normal; serum creatinine &gt; or = 2.2 mg/dL;
             AST/ALT &gt; 2.5 ULN.

          4. Any condition or any medication which may interfere with the conduct of the study.

          5. Current active malignancy other than renal cell cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 7, 2002</study_first_submitted>
  <study_first_submitted_qc>May 7, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2002</study_first_posted>
  <last_update_submitted>October 14, 2011</last_update_submitted>
  <last_update_submitted_qc>October 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal</keyword>
  <keyword>renal cell cancer</keyword>
  <keyword>renal cell carcinoma</keyword>
  <keyword>kidney cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

